Employees: 23
Size Ovid Therapeutics (OVID) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $427M, the 2792nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.26 on 18 Nov 2026.
Performance Over six months the shares fell 5.4%, against -25.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 78.0% over the last twelve months (peer median +7.2%); the operating margin is -4,700.3% (peer median 1.5%).
Valuation It trades at 208.3× enterprise value to sales against a peer median of 2.9× (most expensive of 19).
Capital Return on invested capital runs 78.9 points below its cost of capital (6.5% WACC).
Next results Next results expected around 15 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.45M | $7.25M | $566,000 | $391,695 | $1.50M |
| Revenue growth | — | +1,181% | +45% | -74% | — |
| Gross profit | $1.34M | $6.95M | -$34,000 | -$1.20M | $121,142 |
| EBITDA | -$68.1M | -$42.1M | -$61.3M | -$57.7M | -$54.2M |
| Net income | -$43.1M | -$17.4M | -$26.4M | -$52.3M | -$54.2M |
| Free cash flow | -$57.8M | -$38.3M | -$56.0M | -$45.8M | -$56.5M |
| Capital expenditure | $0 | $0 | $161,000 | $137,455 | $1.42M |
| Total debt | $12.4M | $13.4M | $14.8M | $46.0M | $16.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OVID | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -13.0% | 3rd highest of 21 |
| 6-month return | -5.4% | -25.4% | 6th highest of 21 |
| Distance from 52-week high | -27.2% | -49.4% | 3rd highest of 21 |
| Revenue growth (TTM) | -78.0% | +7.2% | lowest of 19 |
| Operating margin | -4,700.3% | 1.5% | lowest of 19 |
| EV / Sales | 208.3× | 2.9× | most expensive of 19 |
| ROIC minus cost of capital | -78.9 pp | -5.9 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | 0.2× | -9.9% | -3.4% |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |